Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 randomized placebo-controlled trial of intravenous PCN-101 in healthy Japanese males
jRCT2071210139Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Apr 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of r-ketamine in treatment-resistant depression (TRD) (4 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoints: Safety endpoints and Pharmacokinetic endpoints. Started Apr 2022; status: completed.
02
Drugs
r-ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on jRCT2071210139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210139.